Vaccibody announces the closing of the worldwide license and collaboration agreement with Genentech
All antitrust contingencies required to close the agreement with Genentech, regarding the development of individualized neoantigen cancer vaccines, have been satisfied
Oslo, Norway, November 06, 2020 –
Vaccibody AS, a clinical-stage biopharmaceutical company...
VACCIBODY ENTERS INTO WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH GENENTECH, A MEMBER OF THE ROCHE GROUP, TO DEVELOP INDIVIDUALIZED NEOANTIGEN CANCER VACCINES
Vaccibody enters into worldwide, exclusive license and collaboration agreement with Genentech to develop VB10.NEO, individualized neoantigen cancer vaccines
OCTOBER 1, 2020
VACCIBODY LISTS ON OSLO...
